20/20 Biolabs Inc. AIDX
—
0.43
0.01
2.38%
as of 25 Sep
- Market cap
- $5.4M
- P/E
- 0.0×
Follow AIDX
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (211.61%) | 0.00% | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(253.27%) | 0.00% | 0.00% | — | |
Average Days of Receivables |
48.97 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.40) | (0.55) | 0.00 | 0.00 | |
Free Cash Flow |
(4.35) | (4.23) | (5.54) | — | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(56.43%) | (58.10%) | (325.81%) | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
253.90 | 0.00 | 0.00 | — | |
Days of Inventory on Hand |
27.45 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
34.15% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
196.05% | — | — | — | |
Share Based Compensation of Revenue |
34.93% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.67 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
22.54 | 10.83 | 6.61 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.20 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.40) | (0.55) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
(298.16%) | — | — | — |
Columns are period end dates